Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Featured Story
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Date Posted: 4/7/2026. In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking. Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in late March. This sharp downturn has left many wondering if the foundation of this industry leader is cracking.
SpaceX's IPO Could Trigger the Biggest Coin Run Yet
Every major IPO event has sent shockwaves through the crypto market. And this time won’t be any different.
When Musk’s leaked “X” payments plan hit the press, one corner of crypto rallied for months. When Dogecoin got a single tweet from him, it jumped 40% overnight. Click here to see the #1 coin positioned for the next wave.
Key Points
Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment. Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders. Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion. - Special Report: Elon Musk’s $1 Quadrillion AI IPO
A deeper look into Abbott Laboratories' current situation reveals a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market’s pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn't fall without reason; its recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division. This was primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been candid about the challenge and has outlined a clear plan for a turnaround. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 designed to reignite volume growth, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a significant rotation of capital. In periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector and into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. This broad trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works through a short-term recovery, Abbott Laboratories' core remains strong, powered by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model provides a powerful counterbalance to the isolated weakness in nutrition, and the company's true health is most evident in these high-performing areas.
Medical Devices: The Medical Devices division is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. This product line, which enables users to track glucose levels without routine fingersticks, generated over $7.5 billion in sales in 2025 and is a primary driver of Abbott's sustained success. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while its Structural Heart business posted strong organic growth of 8.7%. This strength comes from a portfolio of best-in-class products, such as MitraClip and TriClip, which offer minimally invasive solutions for heart valve repair, as well as a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also pursuing strategic growth through the acquisition of Exact Sciences. Exact Sciences, best known for its non-invasive colon cancer test Cologuard, is a leader in cancer screening and diagnostics. This acquisition would position Abbott as a leader in the rapidly expanding, multi-billion-dollar market for cancer diagnostics, adding a high-growth vertical that could contribute meaningfully to revenue for years to come. This bullish outlook is not just internal—Wall Street shares it. Analysts maintain a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and reflecting the view that the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is its most compelling feature. Abbott Laboratories is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. This track record demonstrates a deep commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price increases the dividend yield for new investors. At current prices, Abbott yields about 2.5%, allowing investors to lock in a higher rate of income from a historically reliable payer. The dividend also appears secure: the payout ratio is roughly 68% of earnings and represents about 37% of cash flow, indicating Abbott generates ample cash to cover its dividend with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott Laboratories seems out of step with its business fundamentals. While temporary headwinds in one division and broader market rotations have weighed on the stock price, Abbott's fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver strong results, the dividend remains a foundation for income investors, and strategic catalysts such as the Exact Sciences acquisition could add meaningful long-term growth. For investors with a multi-year horizon, the present valuation suggests a noteworthy gap between price and intrinsic value—an opportunity worth considering. |
Post a Comment
Post a Comment